NASDAQ:MBRX - Moleculin Biotech Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Moleculin Biotech Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.91 -0.03 (-3.19 %) (As of 01/27/2020 04:00 PM ET) Add Compare Today's Range$0.91Now: $0.91▼$0.9350-Day Range$0.91MA: $0.97▼$1.0452-Week Range$0.78Now: $0.91▼$3.15Volume2,690 shsAverage Volume240,953 shsMarket Capitalization$41.61 millionP/E RatioN/ADividend YieldN/ABeta1.85 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Moleculin Biotech, Inc, a clinical-stage pharmaceutical company, focuses on the development of oncology drug candidates. Its lead drug candidate is liposomal Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML). The company also develops WP1066 Portfolio, an immuno-stimulating STAT3 inhibitor for the treatment of brain tumors, pancreatic cancer, and AML; and WP1122 Portfolio and related molecules for the treatment of glioblastoma multiforme and related central nervous system malignancies. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MBRX Previous Symbol CUSIPN/A CIK1659617 Webhttp://www.moleculin.com/ Phone713-300-5160Debt Debt-to-Equity Ratio0.02 Current Ratio1.67 Quick Ratio1.67Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.53 per share Price / Book1.72Profitability EPS (Most Recent Fiscal Year)($0.51) Net Income$-11,880,000.00 Net MarginsN/A Return on Equity-83.40% Return on Assets-56.62%Miscellaneous Employees9 Outstanding Shares45,730,000Market Cap$41.61 million Next Earnings Date2/20/2020 (Estimated) OptionableNot Optionable Receive MBRX News and Ratings via Email Sign-up to receive the latest news and ratings for MBRX and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:MBRX Rates by TradingView Moleculin Biotech (NASDAQ:MBRX) Frequently Asked Questions What is Moleculin Biotech's stock symbol? Moleculin Biotech trades on the NASDAQ under the ticker symbol "MBRX." How were Moleculin Biotech's earnings last quarter? Moleculin Biotech Inc (NASDAQ:MBRX) released its earnings results on Tuesday, November, 12th. The company reported ($0.09) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.09) by $0.00. View Moleculin Biotech's Earnings History. When is Moleculin Biotech's next earnings date? Moleculin Biotech is scheduled to release their next quarterly earnings announcement on Thursday, February 20th 2020. View Earnings Estimates for Moleculin Biotech. What price target have analysts set for MBRX? 3 brokers have issued 12-month price objectives for Moleculin Biotech's shares. Their forecasts range from $2.00 to $3.00. On average, they anticipate Moleculin Biotech's stock price to reach $2.50 in the next twelve months. This suggests a possible upside of 174.7% from the stock's current price. View Analyst Price Targets for Moleculin Biotech. What is the consensus analysts' recommendation for Moleculin Biotech? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Moleculin Biotech in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Moleculin Biotech. What are Wall Street analysts saying about Moleculin Biotech stock? Here are some recent quotes from research analysts about Moleculin Biotech stock: 1. According to Zacks Investment Research, "Moleculin Biotech, Inc. is a preclinical and clinical-stage pharmaceutical company which focused on the development of anti-cancer drug candidates. The company's lead product candidate is Annamycin, a Phase II clinical stage anthracycline for the treatment of relapsed or refractory acute myeloid leukemia. Moleculin Biotech, Inc. is based in Houston, TX. " (12/31/2019) 2. Maxim Group analysts commented, "Moleculin reported YE18 with a net loss of ($11.9M) and ended the period with ~$7M in cash, runway into 3Q19. The company also has $18M remaining on an equity line. Management continued to execute in 2018 and position its two lead programs (Annamycin and the STAT3 candidates) to reach data points in 2019, which should if positive unlock value for MBRX shareholders. Important in our view is to focus on why these assets are differentiated in the oncology space and how that could translate into a higher probability of success in the clinic. We review in more detail below." (2/26/2019) Has Moleculin Biotech been receiving favorable news coverage? News coverage about MBRX stock has trended somewhat negative recently, InfoTrie Sentiment reports. The research group ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Moleculin Biotech earned a media sentiment score of -1.4 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Moleculin Biotech. Are investors shorting Moleculin Biotech? Moleculin Biotech saw a decline in short interest during the month of December. As of December 31st, there was short interest totalling 1,790,000 shares, a decline of 6.3% from the December 15th total of 1,910,000 shares. Based on an average daily volume of 231,400 shares, the short-interest ratio is currently 7.7 days. Currently, 4.6% of the shares of the company are sold short. View Moleculin Biotech's Current Options Chain. Who are some of Moleculin Biotech's key competitors? Some companies that are related to Moleculin Biotech include Corvus Pharmaceuticals (CRVS), Ovid Therapeutics (OVID), Strongbridge Biopharma (SBBP), ContraFect (CFRX), Aldeyra Therapeutics (ALDX), NuCana (NCNA), Akorn (AKRX), Galectin Therapeutics (GALT), Mustang Bio (MBIO), Avenue Therapeutics (ATXI), Xeris Pharmaceuticals (XERS), Aravive (ARAV), PhaseBio Pharmaceuticals (PHAS), Adamas Pharmaceuticals (ADMS) and CannTrust (CTST). What other stocks do shareholders of Moleculin Biotech own? Based on aggregate information from My MarketBeat watchlists, some companies that other Moleculin Biotech investors own include Rite Aid (RAD), AVEO Pharmaceuticals (AVEO), vTv Therapeutics (VTVT), Exelixis (EXEL), SCYNEXIS (SCYX), AcelRx Pharmaceuticals (ACRX), Synergy Pharmaceuticals (SGYP), Palatin Technologies (PTN), Inovio Pharmaceuticals (INO) and Sierra Oncology (SRRA). Who are Moleculin Biotech's key executives? Moleculin Biotech's management team includes the folowing people: Mr. Walter V. Klemp, Founder, Chairman, Pres & CEO (Age 59)Mr. Jonathan P. Foster, CFO & Exec. VP (Age 55)Dr. Donald H. Picker, Chief Scientific Officer (Age 73)Dr. Waldemar Priebe, Co-Founder and Chairman of Scientific Advisory BoardDr. Robert C. Shepard, Chief Medical Officer (Age 67) Who are Moleculin Biotech's major shareholders? Moleculin Biotech's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Taylor Cottrill Erickson & Associates Inc. (0.22%). View Institutional Ownership Trends for Moleculin Biotech. Which institutional investors are selling Moleculin Biotech stock? MBRX stock was sold by a variety of institutional investors in the last quarter, including Taylor Cottrill Erickson & Associates Inc.. View Insider Buying and Selling for Moleculin Biotech. How do I buy shares of Moleculin Biotech? Shares of MBRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Moleculin Biotech's stock price today? One share of MBRX stock can currently be purchased for approximately $0.91. How big of a company is Moleculin Biotech? Moleculin Biotech has a market capitalization of $41.61 million. The company earns $-11,880,000.00 in net income (profit) each year or ($0.51) on an earnings per share basis. Moleculin Biotech employs 9 workers across the globe.View Additional Information About Moleculin Biotech. What is Moleculin Biotech's official website? The official website for Moleculin Biotech is http://www.moleculin.com/. How can I contact Moleculin Biotech? Moleculin Biotech's mailing address is 5300 MEMORIAL DRIVE SUITE 950, HOUSTON TX, 77007. The company can be reached via phone at 713-300-5160. MarketBeat Community Rating for Moleculin Biotech (NASDAQ MBRX)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 189 (Vote Outperform)Underperform Votes: 166 (Vote Underperform)Total Votes: 355MarketBeat's community ratings are surveys of what our community members think about Moleculin Biotech and other stocks. Vote "Outperform" if you believe MBRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MBRX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/27/2020 by MarketBeat.com StaffFeatured Article: Analyst Ratings Trading
